Confirmed Control Closed Transaction verified biopharmaceuticalseye care therapeuticsophthalmic pharmaceuticals
Oyster Point Pharma acquired by Viatris
Viatris acquired Oyster Point Pharma, an ophthalmic pharmaceuticals brand, on Jan 3, 2023.
Transaction summary
- Target
- Oyster Point Pharma
- Acquirer
- Viatris
- Seller
- -
- Announced
- 2022-11-07
- Geography
- -
- Type
- Acquisition
- Deal type
- Control
- Stake acquired
- -
- First added
- 2026-06-19
- Latest update
- 2026-10-21
Value and multiples
100% enterprise value
Undisclosed
Value not disclosed
Basis: FundComb estimate
Reported price is assumed to be 100% EV unless stated otherwise. Partial-stake estimates are qualified in the basis notes.
EV / revenue
-
Period not stated
Basis: FundComb estimate
EV / EBITDA
20.7x
EBITDA basis not stated
Basis: FundComb estimate
Basis
- The 20.7x EBITDA multiple comes from FundComb’s comps spreadsheet and is not confirmed by a public source; the price, EBITDA amount and period behind it are not stated. Viatris announced that it closed the acquisition of Oyster Point Pharma on 3 January 2023 (PR Newswire).
Source summary
Viatris Closes Acquisitions of Oyster Point Pharma and Famy Life Sciences, Establishing New Viatris Eye Care Division - PR Newswire
ConfirmedContinue your research
Related transaction comps
ophthalmic pharmaceuticals
Aerie Pharmaceuticals, Inc. acquired by Alcon Research, Ltd.
2022-08-22 · Estimated
View transaction → biopharmaceuticalsBiohaven Pharmaceutical acquired by Pfizer
2022-05-10 · Confirmed
View transaction → biopharmaceuticalsGW Pharmaceuticals acquired by Jazz Pharmaceuticals
2021-02-03 · Confirmed
View transaction → biopharmaceuticalsAimmune Therapeutics acquired by Sociétés des Produits Nestlé S.A. / Nestlé Health Science
2020-08-31 · Estimated
View transaction →